Abstract
Patients with schizophrenia are more likely than the general population to have metabolic syndrome and to live around 15 fewer years largely because of cardiovascular death. Recent studies have suggested that antipsychotic polypharmacy may be associated with metabolic disturbance including metabolic syndrome and the mortality related to it. Although antipsychotic polypharmacy is not recommended and there is limited evidence of its benefits, it is nevertheless becoming common in the treatment of schizophrenia. If it is indeed associated with a greater risk of metabolic syndrome, then more widespread use is a serious concern. In this chapter, we review the effects of antipsychotic polypharmacy on mortality, metabolic disturbance, and metabolic syndrome. The results of earlier studies indicate that antipsychotic polypharmacy might increase the risk of some metabolic disturbances and related mortality but not the risk of metabolic syndrome. The effects of antipsychotic polypharmacy on metabolic disturbance and metabolic syndrome may be unchanged in patients with schizophrenia even after changing unhealthy lifestyles. Further studies are still needed to clarify the association between antipsychotic polypharmacy and metabolic disturbance or metabolic syndrome. At present, in cases when antipsychotic polypharmacy is deemed necessary, it is recommended that testing for metabolic parameters should be undertaken more often in patients receiving polypharmacy than in those receiving monotherapy and stricter lifestyle interventions are needed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Abbreviations
- CI:
-
Confidence interval
- HDL:
-
High-density lipoprotein
- LDL:
-
Low-density lipoprotein
- OR:
-
Odds ratio
- RR:
-
Rate ratio
- TG/HDL:
-
The triglycerides/high-density lipoprotein cholesterol ratio
References
Lakka HM, Laaksonen DE, Lakka TA et al (2002) The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288(21):2709–2716
De Hert M, van Winkel R, Van Eyck D et al (2006) Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemiol Ment Health 2:14
Hennekens CH, Hennekens AR, Hollar D et al (2005) Schizophrenia and increased risks of cardiovascular disease. Am Heart J 150(6):1115–1121
Meyer JM, Stahl SM (2009) The metabolic syndrome and schizophrenia. Acta Psychiatr Scand 119(1):4–14
Lehman AF, Lieberman JA, Dixon LB et al (2004) Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 161(2 Suppl):1–56
Miller AL, Hall CS, Buchanan RW et al (2004) The Texas medication algorithm project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry 65(4):500–508
Miller AL, Craig CS (2002) Combination antipsychotics: pros, cons, and questions. Schizophr Bull 28(1):105–109
Schumacher JE, Makela EH, Griffin HR (2003) Multiple antipsychotic medication prescribing patterns. Ann Pharmacother 37(7–8):951–955
Tapp A, Wood AE, Secrest L et al (2003) Combination antipsychotic therapy in clinical practice. Psychiatr Serv 54(1):55–59
Rittmannsberger H, Meise U, Schauflinger K et al (1999) Polypharmacy in psychiatric treatment. Patterns of psychotropic drug use in Austrian psychiatric clinics. Eur Psychiatry 14(1):33–40
Williams CL, Johnstone BM, Kesterson JG et al (1999) Evaluation of antipsychotic and concomitant medication use patterns in patients with schizophrenia. Med Care 37(4 Suppl Lilly):AS81–AS86
Procyshyn RM, Kennedy NB, Tse G et al (2001) Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution. Can J Psychiatry 46(4):334–339
Sim K, Su A, Fujii S et al (2004) Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. Br J Clin Pharmacol 58(2):178–183
Hida H, Faber M, Alberto-Gondouin MC et al (1997) Analysis of prescriptions for psychotropic drugs in a psychiatric hospital. Therapie 52(6):573–578
Anil Yagcioglu AE, Kivircik Akdede BB, Turgut TI et al (2005) A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry 66(1):63–72
Shiloh R, Zemishlany Z, Aizenberg D et al (1997) Sulpiride adjunction to clozapine in treatment-resistant schizophrenic patients: a preliminary case series study. Eur Psychiatry 12(3):152–155
Montgomery J, Winterbottom E, Jessani M et al (2004) Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment. J Clin Psychiatry 65(11):1491–1498
Hollis J, Touyz S, Grayson D et al (2006) Antipsychotic medication dispensing and associated odds ratios of death in elderly veterans and war widows, 2001. Aust N Z J Psychiatry 40(11–12):981–986
Joukamaa M, Heliovaara M, Knekt P et al (2006) Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry 188:122–127
Waddington JL, Youssef HA, Kinsella A (1998) Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry 173:325–329
Baandrup L, Gasse C, Jensen VD et al (2010) Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case–control study. J Clin Psychiatry 71(2):103–108
Nagamine T (2010) Abnormal laboratory values during the acute and recovery phases in schizophrenic patients: a retrospective study. Neuropsychiatr Dis Treat 6:281–288
Kessing LV, Thomsen AF, Mogensen UB et al (2010) Treatment with antipsychotics and the risk of diabetes in clinical practice. Br J Psychiatry 197(4):266–271
Honer WG, Thornton AE, Chen EY et al (2006) Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 354(5):472–482
Weiner E, Conley RR, Ball MP et al (2010) Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine. Neuropsychopharmacology 35(11):2274–2283
Fleischhacker WW, Heikkinen ME, Olie JP et al (2010) Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 13(8):1115–1125
Muscatello MR, Bruno A, Pandolfo G et al (2011) Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. Schizophr Res 127(1–3):93–99
Kane JM, Correll CU, Goff DC et al (2009) A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry 70(10):1348–1357
Goodwin G, Fleischhacker W, Arango C et al (2009) Advantages and disadvantages of combination treatment with antipsychotics ECNP consensus meeting, March 2008, Nice. Eur Neuropsychopharmacol 19(7):520–532
Riordan H, Antonini P, Murphy M (2011) Atypical antipsychotics and metabolic syndrome in patients with schizophrenia: risk factors, monitoring, and health care implications. Am Health Drug Benefits 4(5):292–302
Krane-Gartiser K, Breum L, Glumrr C et al (2011) Prevalence of the metabolic syndrome in Danish psychiatric outpatients treated with antipsychotics. Nord J Psychiatry 65(5):345–352
Huang MC, Lu ML, Tsai CJ et al (2009) Prevalence of metabolic syndrome among patients with schizophrenia or schizoaffective disorder in Taiwan. Acta Psychiatr Scand 120(4):274–280
Correll CU, Frederickson AM, Kane JM et al (2007) Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res 89(1–3):91–100
Connolly M, Kelly C (2005) Life style and physical health in schizophrenia. Adv Psychiatry Treat 11:125–132
Misawa F, Shimizu K, Fujii Y et al (2011) Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study. BMC Psychiatry 11:118
Silver H, Kogan H, Zlotogorski D (1990) Postural hypotension in chronically medicated schizophrenics. J Clin Psychiatry 51(11):459–462
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Misawa, F., Yasuo, F., Okumura, Y., Ito, H. (2013). Metabolic Syndrome and Antipsychotic Polypharmacy. In: Ritsner, M. (eds) Polypharmacy in Psychiatry Practice, Volume II. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-5799-8_8
Download citation
DOI: https://doi.org/10.1007/978-94-007-5799-8_8
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-5798-1
Online ISBN: 978-94-007-5799-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)